Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated Jun 03, 2025, titled "Sun Pharma Announces Top-Line Results from the Phase 2 Clinical Trials Evaluating SCD-044 for Moderate to Severe Psoriasis and Atopic Dermatitis".